Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
Publishing timestamp: 2024-04-25 11:12:55
Summary
Merck reported strong first-quarter revenue and earnings, driven by sales of Keytruda and vaccine products. The company raised its full-year outlook and is making progress in preparing for Keytruda's patent expiration in 2028. Additionally, Merck is seeing success with new drug launches and cost-cutting efforts.
Sentiment: POSITIVE
Tickers: FDS, MRK, MRNA, PFE, ELAN,
Keywords: earnings, factset research systems inc, biotech and pharmaceuticals, pfizer inc, merck & co inc, moderna inc, business news, elanco animal health inc, breaking news, biotechnology, pharmaceuticals, health care industry, business,
Source: https://www.cnbc.com/2024/04/25/merck-mrk-earnings-q1-2024.html